Bridgewater, NJ, United States of America

Byungchan Kim

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Insmed Incorporated. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byungchan Kim. Retrieved from https://idiyas.com/inventor/byungchan-kim-kuii2b50

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Byungchan Kim: Inventor in Pharmaceutical Research

Introduction

Byungchan Kim is an inventor based in Bridgewater, New Jersey, whose patent work concerns pharmaceutical compounds and potential treatments. He is associated with Insmed Incorporated and is credited with 1 patent.

Latest Patents

Kim’s patent, “Linear dipeptidyl peptidase 1 inhibitors and uses thereof,” describes compounds of Formula (I), including pharmaceutically acceptable salts and deuterated forms. It also covers pharmaceutical compositions containing these compounds and methods for using them, including treatment of diseases that may be treated with a DPP1 inhibitor.

Career Highlights

Kim’s listed invention reflects work in drug discovery and the development of potential therapeutic approaches. The patent focuses on DPP1 inhibitors and their possible pharmaceutical applications.

Collaborations

Kim is associated with Insmed Incorporated. Adam J. Plaunt and Gianpaolo Gobbo are identified as some of his coworkers.

Conclusion

Byungchan Kim’s patent documents an invention focused on DPP1 inhibitors and their potential use in pharmaceutical compositions and disease treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…